• Mashup Score: 0

    Skin diseases from psoriasis to melanoma affect as many as one in three Americans at any given time. Kathleen Green, PhD, has greatly advanced basic molecular research related to skin diseases. She discusses recent discoveries in her lab that could lead to future therapeutic targets.

    Tweet Tweets with this article
    • Kathleen Green, PhD, (@kjgreen47) Associate Director of Basic Sciences Research @LurieCancer, discusses discoveries in her lab that may lead to new therapeutic targets & #BetterCancerCare. Listen to the #BreakthroughsPodcast https://t.co/iyrG5Ho4Ap @NUFeinbergMed @KathyGreenLab… https://t.co/w9IEIESWoZ

  • Mashup Score: 2
    Home - 1 year(s) ago

    We recognize the women leaders who attained status of full professor and celebrate our current leadership who work to improve patient care, scientific research, and medical education.

    Tweet Tweets with this article
    • Women make up over half of our medical students & trainees at @NUFeinbergMed and lead over $237 million in funded research. On #InternationalWomensDay, learn about some of our senior leaders @LurieCancer inspiring progress @NorthwesternMed: https://t.co/InY5ljJbiH… https://t.co/8MVCyP83Oc https://t.co/BuxmRHPisL

  • Mashup Score: 0

    For more than two decades, The H Foundation has donated crucial funding to the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Their support is specifically earmarked for basic science research—the fundamental laboratory studies that lead to new scientific knowledge and ultimately fuel ideas for better therapies for patients.

    Tweet Tweets with this article
    • For more than 20 years, our partners @The_HFoundation have raised crucial funds for basic science research @LurieCancer — supporting studies in the lab that lead to new scientific knowledge and fuel breakthroughs for patients. https://t.co/DcZi57uNlq https://t.co/mFuU0eNLNs

  • Mashup Score: 1
    Faculty Profile - 2 year(s) ago

    Focus of WorkBioI have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based…

    Tweet Tweets with this article
    • RT @TischCancer: We look forward to hearing about immune checkpoint inhibitors from Dr. Jeffrey Sosman on June 26. https://t.co/35uGll3dOk…